Oxford Biomedica and Novartis have agreed to extend an agreement to manufacture lentiviral vectors for several of the Swiss drugmaker’s CAR-T therapies. The move extends the partners' collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback